Oakworth Capital Inc. Acquires 79 Shares of Eli Lilly and Company (NYSE:LLY)

by · The Cerbat Gem

Oakworth Capital Inc. increased its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 2.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,884 shares of the company’s stock after purchasing an additional 79 shares during the period. Oakworth Capital Inc.’s holdings in Eli Lilly and Company were worth $3,441,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. M&G Plc purchased a new stake in Eli Lilly and Company during the first quarter valued at $8,896,000. Virtu Financial LLC bought a new position in shares of Eli Lilly and Company in the 1st quarter worth approximately $2,138,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Eli Lilly and Company by 19.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock worth $7,699,000 after buying an additional 1,620 shares during the last quarter. Mutual Advisors LLC grew its position in Eli Lilly and Company by 404.8% during the first quarter. Mutual Advisors LLC now owns 62,598 shares of the company’s stock valued at $48,699,000 after buying an additional 50,197 shares during the period. Finally, Private Advisor Group LLC increased its holdings in Eli Lilly and Company by 0.6% during the first quarter. Private Advisor Group LLC now owns 76,282 shares of the company’s stock valued at $59,345,000 after buying an additional 430 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.5 %

NYSE LLY opened at $901.98 on Tuesday. The stock has a market cap of $857.25 billion, a PE ratio of 133.45, a PEG ratio of 2.79 and a beta of 0.42. The company’s 50-day moving average price is $921.65 and its 200-day moving average price is $859.57. Eli Lilly and Company has a 12 month low of $547.61 and a 12 month high of $972.53. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Equities research analysts forecast that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

LLY has been the subject of several analyst reports. Morgan Stanley restated an “overweight” rating and issued a $1,106.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. BMO Capital Markets raised their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Barclays boosted their price objective on Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Guggenheim lifted their price target on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a report on Friday, August 16th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $1,025.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, October 3rd. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $1,002.24.

Get Our Latest Stock Analysis on LLY

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Stories